{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.00","groupDescription":"Strata are: Enrollment Stage, PD-L1 Status, BAJORIN Risk Factor Score and Stratum 4 for all participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0542","paramType":"Hazard Ratio (HR)","paramValue":"0.80","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.28","upperLimit":"20.24","value":"12.06"},{"comment":"Not evaluable due to sample size is very small and not enough events at later times to estimate the upper bound of the CI.","groupId":"OG001","lowerLimit":"18.40","upperLimit":"NA","value":"32.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"451"}],"units":"Participants"}],"description":"Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG001","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"}],"paramType":"MEDIAN","populationDescription":"The patient reported outcome (PRO)-evaluable population is defined as participants in the ITT populations for comparisons of the Placebo+Chemo Arm versus Atezolizumab+Chemo Arm who have a baseline and at least one post-baseline assessment. The ITT population for the comparison of Atezo+Chemo Arm vs. Placebo+Chemo Arm included participants enrolled in Stage 1 and Stage 2, which consisted of 451 paarticipants in the Atezo+Chemo Arm and 400 participants in the Placebo+Chemo Arm.","reportingStatus":"POSTED","timeFrame":"Up to approximately 73 months","title":"Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm","type":"SECONDARY","unitOfMeasure":"Months"}